IMIDomics, a VHIR spinoff cofounded by Dr Marsal won in 2022 the Bioèxit Award by CataloniaBio & HealthTech. H2020 EU project DoCTIS coordinated by Drs Marsal and Julià, has generated preliminary results of SC RNA-Seq data from 170 IMID patients and offers insights of translational significance. A SC RNA-Seq data has been generated in JIA (Drs Lopez, Moreno). Dr Cortés participates in the innovative Clinical Trial (CT) to use CAR-T therapy in SLE. The CT Unit in rheumatic disorders lead by M Sender is growing. A national wide project in IMID Check point inhibitors treated patients is being co/lead by Dr Trallero and VHIO. In SpA, Drs Michelena and Erra started a new study using ML techniques to better characterize the SpA cohort. PIs were granted by ISCIII (Drs Julià, Cortés, Solé), MMadrileña (Dr Alegre), SER (Dr Marsal), raising >750.000€. Drs Almirall, Pluma and Serrat presented their dissertation. IMID-Biobank (Dr Tortosa) continues to collect longitudinal IMID patients samples.

Group Leader
Antonio Julia Cano

Principal Investigator (PI)
José Alegre, Josefina Cortés, Juan José de Agustín, María Lopez, Ernesto Trallero, Jesús Castro, Mayte Serrat, Cristina Solé, Raúl Tortosa

Researchers
Mireia Barceló, Adrià Aterido, Alba Erra, Jordi Lladós, Andrea Pluma, Núria Palau, Ramon Sanmartín, Miriam Almirall, Talia Franco

PhD Students
Estefanía Moreno, Helena Borrell, María Pascual, Gustavo Áñez, Judith Fernández, Mireia López, Xabier Michelena, Laia Martínez, Rafael Touriño, Luís Coronel, Esther Espartal, Alejandro Gómez, Sebastián Sandoval, Hugo Fernando Ávalos, Ana Daniela Ulloa, Jorge Alcaraz, Adriana Cabrera, Irene Bonafonte

Lab Technicians
Edgar Núñez, Aitor Ruiz

Nursing and Technical Staff
Alba Frías, Anna Tirado, María Royo, Ares Sellés, Marta Musté, Anna Roig, Natalia Boix, Mercè Fabregat, Elena Granell, Montserrat Sender

31

PUBLICATIONS

54.8%

%Q1

278

IMPACT FACTOR

8.98

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Julia A, Gomez A, Lopez-Lasanta M, Blanco F, Erra A, Fernandez-Nebro A, Mas AJ, Perez-Garcia C, Vivar MLG, Sanchez-Fernandez S, Alperi-Lopez M, Sanmarti R, Ortiz AM, Fernandez-Cid CM, Diaz-Torne C, Moreno E, Li T, Martinez-Mateu SH, Absher DM, Myers RM, Molina JT, Marsal S
Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis
EBioMedicine. 2022 Jun; 80:104053. doi: 10.1016/j.ebiom.2022.104053. Epub 2022 May 13
DOI: doi: 10.1016/j.ebiom.2022.104053
IF: 11.21

Castro-Marrero, Jesús, Domingo, Joan Carles, Cordobilla, Begona, Ferrer, Roser, Giralt, Marina, Sanmartin-Sentanes, Ramon, Alegre-Martin, Jose et al.
Does Dietary Coenzyme Q10 plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?
Antioxid Redox Signal. 2022 Apr;36(10-12):729-739.
DOI: doi: 10.1089/ars.2022.0018
IF: 7.47

Ferrete-Bonastre AG, Cortes-Hernandez J, Ballestar E
What can we learn from DNA methylation studies in lupus?
Clin Immunol. 2022 Jan; 234:108920. doi: 10.1016/j.clim.2021.108920. Epub 2021 Dec 29.
DOI: doi: 10.1016/j.clim.2021.108920
IF: 10.19

Michelena X, Lopez-Medina C, Erra A, Juanola X, Font-Ugalde P, Collantes E, Marzo-Ortega H
Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
RMD Open. 2022 Dec;8(2):e002513. doi: 10.1136/rmdopen-2022-002513
DOI: doi: 10.1136/rmdopen-2022-002513
IF: 5.81

Deya-Martinez A, Riviere JG, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P, Blanco Lobo P, Abu Jamra SR, Esteve-Sole A, Kanderova V, Garcia-Garcia A, Lopez-Corbeto M, Martinez Pomar N, Martin-Nalda A, Alsina L, Neth O, Olbrich P
Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature
J Clin Immunol. 2022 Jul;42(5):1071-1082. doi: 10.1007/s10875-022-01257-x. Epub 2022 Apr 29
DOI: doi: 10.1007/s10875-022-01257-x
IF: 8,54

DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES
Principal Investigator: Sara Marsal Barril
Agency: EUROPEAN COMMISSION. DOCTIS_H2020_SC1-BHC2019
Funding: 1,122,820 (6.2 M€)
Period: 01/01/2020 - 31/12/2025

Estratificación de pacientes con artritis reumatoide en la terapia anti-TNF. Caracterización espacial del transcriptoma de la membrana sinovial asociada a la respuesta a tratamiento y asociación a biomarcadores proteómicos.
Principal Investigator: Antonio Julia Cano
Agency: Instituto de Salud Carlos III. PI21/01185
Funding: 196,020 €
Period: 01/01/2022 - 31/12/2024

Estratificación de la severidad de la fatiga en el síndrome de COVID persistente: nuevas estrategias terapéuticas
Principal Investigator: José Alegre Martin
Agency: Fundación Invest. Médica Mutua Madrileña. MUTUA_MADRILEÑA/202ALEGRE
Funding: 109,998 €
Period: 20/07/2022 - 19/07/2025

Inmunomonitorización personalizada para estratificar los pacientes con lupus eritematoso sistémico
Principal Investigator: Josefina Cortes Hernández
Agency: Instituto de Salud Carlos III. PI21/00287
Funding: 141,570 €
Period: 01/01/2022 - 31/12/2024

Ayudas para facultativos investigadores
Principal Investigator: IP: Sara Marsal Barril
Agency: Fundación Española de Reumatología _ FER/RECERCA/2021/MARSAL
Funding: 135,000 €
Period: 14/02/2022 - 13/02/2025

METHOD TO PREDICT THE LACK OF RESPONSE TO ANTI-TNF ALPHA THERAPIES
Priority Number: PCT/EP2014/066604 (US)
Priority Date: 1/08/2014
Applicants: 66% VHIR, 33,3 % H. Clínic

RISK LOCUS FOR PSORIATIC ARTHRITIS
Priority Number: 62/151,952 (PCT)
Priority Date: 23/04/2015
Applicants: VHIR, CLINIC, IGTP

METHOD TO PREDICT RESPONSE TO TREATMENT WITH ANTI-TNF ALPHA AGENTS
Priority Number: EP14179452.9 (PCT)
Priority Date: 1/08/2014
Applicants: VHIR

Pronóstico de respuesta al tratamiento con anti-TNFalfa en pacientes de artritis reumatoide
Priority Number: P201330650 (PCT)
Priority Date: 3/05/2013

METODO IN VITRO Y KIT PARA EL PRONOSTICO O PREDICCION DE LA RESPUESTA POR PARTE DE PACIENTES CON ARTRITIS REUMATOIDE AL TRATAMIENTO CON AGENTES BLOQUEANTES DEL FACTOR TNF alfa (INFLIXIMAB)
Priority Number: P200802713 (ES)
Priority Date: 24/09/2008
Applicants: VHIR